Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New feature: Introducing the Finviz Matrix

Eikon Therapeutics, Inc.

Contributing Author

Recent Articles by Eikon Therapeutics, Inc.

Sep-03	Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer EIKN GlobeNewswire
Aug-26	Eikon Therapeutics to Participate in Investor Conferences in September 2026 EIKN GlobeNewswire
Aug-18	Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald EIKN +11.27% GlobeNewswire
Aug-13	Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates EIKN EIKN +6.97% GlobeNewswire
Aug-11	Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma EIKN +5.14% GlobeNewswire
Aug-10	Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board EIKN GlobeNewswire
Jul-27	Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer EIKN +11.01% GlobeNewswire
Jul-20	Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress EIKN GlobeNewswire
Jun-25	Eikon Therapeutics to Join the Russell 3000 Index EIKN EIKN +16.24% GlobeNewswire
Jun-08	Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors EIKN GlobeNewswire
May-30	Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology EIKN GlobeNewswire
May-21	Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology EIKN GlobeNewswire
May-11	Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates EIKN EIKN +15.88% GlobeNewswire
Mar-30	Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates EIKN GlobeNewswire
Feb-04	Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering EIKN GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)